AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca strikes $1.2bn obesity drug deal with China's CSPC
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is paying $1.2 billion up-front to seal a tie-up with a Chinese pharma giant aimed at expanding its weight-loss drug pipeline, as it looks to compete in a fast-growing market against the likes of Novo Nordisk's Ozempic and Eli Lilly's Tirzepatide. The agreement with Hong Kong-listed CSPC Pharmaceutical Group gives the FTSE 100 group global rights outside China to eight drug programmes, including one that is ready to enter human trials.
AstraZeneca sets out $15 billion China investment during Starmer visit
UK drugmaker AstraZeneca said on Thursday it would invest $15 billion in China through 2030 to expand medicines manufacturing and research and development, an announcement made during British Prime Minister Keir Starmer's visit to Beijing.
AstraZeneca the 'top pick' among European pharmas - broker
Analysts at Citi see AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) as 'the top pick' among European pharmaceutical firms. and rate the FTSE 100 stock as a 'buy'.
Why Astrazeneca (AZN) Outpaced the Stock Market Today
Astrazeneca (AZN) closed at $94.23 in the latest trading session, marking a +1.38% move from the prior day.
AstraZeneca to delist from Nasdaq, join NYSE in February
AstraZeneca on Tuesday said it would delist its American Depositary Shares and debt securities from Nasdaq and complete a direct listing of its ordinary shares and debt on the New York Stock Exchange, effective after market close on January 30, 2026.
UK drugmakers face tougher test as pharma rally cools
The next earnings season for European pharmaceuticals is shaping up as a test of discipline rather than momentum, with UK stocks firmly in the spotlight. That is the message from Deutsche Bank, which says the sector's strong start to the year has already pulled forward some optimism.
AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AstraZeneca: Oncology Dominance Justifies New All-Time Highs
AstraZeneca started 2026 on a high note. On January 7, its stock reached an all-time high of $95.94. The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises.
Healthcare Dividend Stocks: The Recession-Proof Income Play for 2026
If a recession were to hit, it's a foregone conclusion that people won't stop taking their prescriptions, and they won't cancel major medical treatments.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) concluded the recent trading session at $94.01, signifying a -1.21% move from its prior day's close.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
